Buparlisib (BKM120, NVP-BKM120)

製品コードS2247

Buparlisib (BKM120, NVP-BKM120)化学構造

分子量(MW):410.39

Buparlisib (BKM120, NVP-BKM120)は1種のセレクティブPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は52 nM/166 nM/116 nM/262 nMそれぞれに分かれます。BKM120 (NVP-BKM120, Buparlisib)はVPS34、mTORとDNAPKに作用する効果が良くなくて、PI4Kβにほとんど活性を表しません。臨床2期。

サイズ 価格 在庫  
JPY 39164.73 あり
JPY 24477.96 あり
JPY 46076.16 あり
JPY 139668.35 あり

文献中の引用(37)

カスタマーフィードバック(5)

  • Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 Buparlisib (BKM120, NVP-BKM120)は1種のセレクティブPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は52 nM/166 nM/116 nM/262 nMそれぞれに分かれます。BKM120 (NVP-BKM120, Buparlisib)はVPS34、mTORとDNAPKに作用する効果が良くなくて、PI4Kβにほとんど活性を表しません。臨床2期。
ターゲット
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外試験

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M4\ycWN6fG:2b4jpZ{BCe3OjeR?= NIXLfI84OiCq NYqzPXlZTE2VTx?= NXrHe3o2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> NIPzd|EzPDlyMEK2Oi=>
DU145 NXXOVplvS3m2b4TvfIlkKEG|c3H5 M{Pz[FczKGh? MkT4SG1UVw>? MoL1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP NVvoWGU4OjR7MECyOlY>
A2780 MWfDfZRwfG:6aXOgRZN{[Xl? NVPZbHdZPzJiaB?= MWTEUXNQ NFHwWnZEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN M{jEUFI1QTByMk[2
U87MG MXLDfZRwfG:6aXOgRZN{[Xl? NV\SZoVUPzJiaB?= M2DIWGROW09? MmD4R5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?= MnLHNlQ6ODB{Nk[=
A2780 M3O3ZmZ2dmO2aX;uJGF{e2G7 MVWxJIg> M370bWROW09? NVK0[WFoUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= NVfXXnFCOjR7MECyOlY>
DU145 NHToUFZHfW6ldHnvckBCe3OjeR?= M3\GTVEhcA>? NFzHSGtFVVOR MoDVTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? M4K1eFI1QTByMk[2
A2780 NHv4cFhHfW6ldHnvckBCe3OjeR?= Mlm4NUBp MXfEUXNQ MWnJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCHQ{WwJI9nKDBwMEe0JO69VQ>? MnTwNlQ6ODB{Nk[=
MCF7 NUPuWGRVTnWwY4Tpc44hSXO|YYm= M4jkOlEhcA>? NWrpeGNKTE2VTx?= Ml7iTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO NF24WlkzPDlyMEK2Oi=>
U87MG MojXSpVv[3Srb36gRZN{[Xl? NH7WTmkyKGh? NV3sdFVqTE2VTx?= MV3Jcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCHQ{WwJI9nKDBwMUOg{txO MWSyOFkxODJ4Nh?=
A2780 NWLYeXgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO5UlI4OiCq NX;6To9pTE2VTx?= NW[yb5FFTUN3ME2wMlUzKM7:TR?= MUKyOFkxODJ4Nh?=
SKMES-1 M4jTb2N6fG:2b4jpZ{BCe3OjeR?= NETKNJEyKM7:TR?= MVG3NkBp NGrZeY5KdmS3Y3XzJINmdGxiZHXheIg> NV:0VW12OjZyMUOzNVg>
H596 MUnGeY5kfGmxbjDBd5NigQ>? Mn;6NUDPxE1? MUPJcZBicXK|IHPlcIwhdWmpcnH0bY9v MYKyOlAyOzNzOB?=
HCC2450 NIXS[XNHfW6ldHnvckBCe3OjeR?= MXGxJO69VQ>? MXLJcZBicXK|IHPlcIwhcW64YYPpc44> Mkf0NlYxOTN|MUi=
A549 M4fFPWZ2dmO2aX;uJGF{e2G7 NIHiO4w2ODBibl2= NXLKeZNGPDhiaB?= NYXNT4VxTE2VTx?= NYLMPGlYUW6qaXLpeJMhSWu2IHHjeIl3[XSrb36= NYHpVYd{OjV7M{eyPVk>
A549 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofVNUDPxE1? NWD4R3pMPzJiaB?= NXfId41YTE2VTx?= M{jCWGlvcGmkaYTzJINmdGxiZ4Lve5Rp MYqyOVk{PzJ7OR?=
H522 NYXLfVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nUOFEh|ryP M3W1XFczKGh? MmPSSG1UVw>? M1iwZWlvcGmkaYTzJINmdGxiZ4Lve5Rp MVKyOVk{PzJ7OR?=
LNCaP MoXhSpVv[3Srb36gRZN{[Xl? M2n5dlEh|ryP MlHkV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? NWjmR41ZOjV|NkC3PVk>
LNCaP95 NF:wWGhHfW6ldHnvckBCe3OjeR?= NWHYT25IOSEQvF2= NYPhWGNbW3WycILld5NmeyCyLVHLWEBt\X[nbIO= MmjpNlU{PjB5OUm=
HCT-15 NH;xdXNCeG:2b4Ppd{BCe3OjeR?= M2r5O|ExKM7:TR?= NUfZTlNlPDhiaB?= NXrlT|NPTE2VTx?= M1XjSWlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xOUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MV6yOVE2OjJ2NR?=
HCT-116 Mn31RZBwfG:|aYOgRZN{[Xl? M2jVXFExKM7:TR?= MmDpOFghcA>? NEP6OmFFVVOR MXrJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NULIPY5jOjVzNUKyOFU>
NCI-H460 NFr1UJZCeG:2b4Ppd{BCe3OjeR?= NUSxTYNUOTBizszN MYW0PEBp NGryOG9FVVOR NGKyfGhKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S|cH;0JI12fGG2aX;u MWOyOVE2OjJ2NR?=
SKOV-3 M3LsZ2Fxd3Sxc3nzJGF{e2G7 MnnhNVAh|ryP MXy0PEBp MnXDSG1UVw>? NIPKT5FKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCVS1;WMVMh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MX6yOVE2OjJ2NR?=
BSY-1 NWK3TGxUSXCxdH;zbZMhSXO|YYm= Mln1NVAh|ryP NUDBSIlkPDhiaB?= MVjEUXNQ M{G1PWlv\HWlZYOgZZBweHSxc3nzJIlvKEKVWT2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NGfhcWIzPTF3MkK0OS=>
MKN-1 NHHPTHpCeG:2b4Ppd{BCe3OjeR?= NITmNpQyOCEQvF2= NVrXeJBIPDhiaB?= MWfEUXNQ MorITY5lfWOnczDhdI9xfG:|aYOgbY4hVUuQLUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NUj0NYduOjVzNUKyOFU>
NCI-H522 MWHBdI91d3OrczDBd5NigQ>? MWixNEDPxE1? M1uxZVQ5KGh? M{PTVWROW09? MXjJcoR2[2W|IHHwc5B1d3Orcx?= NYjmXG4xOjVzNUKyOFU>
OVCAR-3 MlvrRZBwfG:|aYOgRZN{[Xl? MV:xNEDPxE1? MnyzOFghcA>? M4foXGROW09? NH;3NlRKdmS3Y3XzJIFxd3C2b4Ppdy=> M4\LN|I2OTV{MkS1
HBC-5 NV\WO4ZMSXCxdH;zbZMhSXO|YYm= M3LyVlExKM7:TR?= MX:0PEBp MXvEUXNQ MkK3TY5lfWOnczDhdI9xfG:|aYO= MYKyOVE2OjJ2NR?=
RXF-631L NYO4UIhKSXCxdH;zbZMhSXO|YYm= MVyxNEDPxE1? MmnWOFghcA>? MnfOSG1UVw>? MoTlTY5lfWOnczDhdI9xfG:|aYO= MonhNlUyPTJ{NEW=
MKN-45 Ml61RZBwfG:|aYOgRZN{[Xl? MXqxNEDPxE1? MXu0PEBp M4DRbGROW09? MlTrTY5lfWOnczDhdI9xfG:|aYO= M1SzfVI2OTV{MkS1
BON-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWi1NFAhdk1? M{nGfFExKGR? NF3temVFVVOR M4fyfWlvcGmkaYTzJINmdGxiZ4Lve5Rp NUS0Zo1kOjVyMk[yPVI>
BON-1 M1:2XmZ2dmO2aX;uJGF{e2G7 NUnqe3dXPTByIH7N NV;XWIhwPCCq MnjPSG1UVw>? M1f5XGlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= MoPsNlUxOjZ{OUK=
QGP-1 NHnqb29HfW6ldHnvckBCe3OjeR?= NUHmZWVPPTByIH7N Ml3tOEBp M{\iXmROW09? MmDsTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= MlnLNlUxOjZ{OUK=
Huh7 M33VUGZ2dmO2aX;uJGF{e2G7 MYqxJO69VQ>? M2H5VFEhcA>? NXO1TY0xTE2VTx?= MojRTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR? MknkNlUxODR2MEO=
BNL M3zHUGZ2dmO2aX;uJGF{e2G7 NHvUeGQyKM7:TR?= MVKxJIg> NX7I[HRzTE2VTx?= NWW1ZZFoUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4 NIrZbZkzPTByNESwNy=>
MDA-MB-175 NEn5fW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XxNVEh|ryP Ml75OUBl NWnWTHhoTE2VTx?= MVjJR|UxRDFizszN M4Tod|I1QDd7N{m2
MDA-MB-134 NYCwNml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH3cpl[OSEQvF2= NEH3dVQ2KGR? NX7hWpJJTE2VTx?= MVTJR|UxRDFizszN NF\jVpIzPDh5OUe5Oi=>
HCC1500 NHfWeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnmV3hUOSEQvF2= MWS1JIQ> MnzoSG1UVw>? M1;H[WlEPTB:MTFOwG0> MlOwNlQ5Pzl5OU[=
EFM-19 M3LWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXaZXBwOSEQvF2= MX61JIQ> Mof5SG1UVw>? NV36PJVpUUN3MEyxJO69VQ>? Ml3CNlQ5Pzl5OU[=
ZR-75-30 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TkW|Eh|ryP NYHGPFVuPSCm M{HwRWROW09? NEj0b3NKSzVyPEGg{txO MWKyOFg4QTd7Nh?=
MDA-MB-361 NUOzR|dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XjflEh|ryP M2HJRVUh\A>? M{XTO2ROW09? MXXJR|UxRDFizszN NUn1dpF7OjR6N{m3PVY>
T-47D MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDUSGR[OSEQvF2= MkPnOUBl MkXhSG1UVw>? MoL2TWM2ODxzIN88US=> M{i1XVI1QDd7N{m2
SK-BR-3 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Da[lEh|ryP NHX2OZk2KGR? NWXCO21GTE2VTx?= NVnZ[2M2UUN3MEyxJO69VQ>? NYHNRoxyOjR6N{m3PVY>
UACC-732 NIe3Vo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjHXZBZOSEQvF2= M4Pu[VUh\A>? NELHeoxFVVOR Mne5TWM2ODxzIN88US=> Moe0NlQ5Pzl5OU[=
BT-474 NWf3Nnh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSxJO69VQ>? NIfUT|A2KGR? MnfhSG1UVw>? MV;JR|UxRDFizszN NXvEVoZTOjR6N{m3PVY>
HCC202 NFuxcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nMblEh|ryP MoTiOUBl MnH6SG1UVw>? MkXCTWM2ODxzIN88US=> NWfwWGxoOjR6N{m3PVY>
MCF7 NYPVNm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfNNUDPxE1? NITLTYs2KGR? NIH3S21FVVOR NVvG[mFCUUN3MEyxJO69VQ>? MoTQNlQ5Pzl5OU[=
MDA-MB-415 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELlfXkyKM7:TR?= MUC1JIQ> M1XWR2ROW09? NVi0R4hCUUN3MEyxJO69VQ>? NE\Cd2wzPDh5OUe5Oi=>
MDA-MB-453 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;sNUDPxE1? NXnXcVZMPSCm MlvHSG1UVw>? M3;jXmlEPTB:MTFOwG0> MUWyOFg4QTd7Nh?=
ZR-75-1 NVz4XmdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f5U|Eh|ryP NEK3eI82KGR? Mn\5SG1UVw>? MV;JR|UxRDFizszN MUOyOFg4QTd7Nh?=
HCC38 M3rGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xJO69VQ>? NIDLZnk2KGR? MWDEUXNQ M3PHU2lEPTB:MTFOwG0> M2\aWlI1QDd7N{m2
HCC1419 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnPWYxTOSEQvF2= MVu1JIQ> MWnEUXNQ NWXvNWdYUUN3MEyxJO69VQ>? MmTyNlQ5Pzl5OU[=
UACC-812 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYXoE4OSEQvF2= M3fMbFUh\A>? M1qydmROW09? M3nVOmlEPTB:MTFOwG0> MlXYNlQ5Pzl5OU[=
HCC1187 NWPYSpNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XqRVEh|ryP NGraSGw2KGR? Mmj0SG1UVw>? NFLKd|FKSzVyPEGg{txO MmfrNlQ5Pzl5OU[=
KPL-1 NF;t[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLkNUDPxE1? MX[1JIQ> MYjEUXNQ NHnueo9KSzVyPEGg{txO MYmyOFg4QTd7Nh?=
SUM-225 Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKxJO69VQ>? Mmi5OUBl MULEUXNQ MX;JR|UxRDFizszN NVTibJZXOjR6N{m3PVY>
EFM-192A NYHzVoo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxJO69VQ>? M3\FXlUh\A>? NXXMXpRUTE2VTx?= NXH2cWxxUUN3MEyxJO69VQ>? NFjHW|gzPDh5OUe5Oi=>
JIMT-1 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxJO69VQ>? NUHleGtjPSCm Ml2zSG1UVw>? MV;JR|UxRDFizszN NU\uVpdPOjR6N{m3PVY>
HCC1143 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn5c|UyKM7:TR?= NHPUd3I2KGR? MXvEUXNQ NHvMZoRKSzVyPEGg{txO M1LIZVI1QDd7N{m2
HCC2218 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PjSVEh|ryP MWG1JIQ> NWC5PFlITE2VTx?= MlXtTWM2ODxzIN88US=> MWqyOFg4QTd7Nh?=
MDA-MB-468 NFPVWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuxJO69VQ>? NV;BbIFHPSCm NVvQeIg{TE2VTx?= Mm[2TWM2ODxzIN88US=> MkK3NlQ5Pzl5OU[=
BT-20 M1;6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfYNUDPxE1? NHPrTZY2KGR? NH\PPVBFVVOR NF6yNnVKSzVyPEGg{txO MoHHNlQ5Pzl5OU[=
MDA-MB-435 NF7VXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DsW|Eh|ryP MojuOUBl M1PwcGROW09? NIrBblZKSzVyPEGg{txO MmfvNlQ5Pzl5OU[=
BT-549 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jOOVEh|ryP NES3NlE2KGR? NGPlTYFFVVOR M4PWXmlEPTB:MTFOwG0> MVOyOFg4QTd7Nh?=
HCC1806 NFjwN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHINUDPxE1? NHXqZVc2KGR? MYXEUXNQ NWPIbplNUUN3MEyxJO69VQ>? M1\FWVI1QDd7N{m2
HCC1937 NI\JbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPheWgzOSEQvF2= NF7Me4k2KGR? MUnEUXNQ MofVTWM2ODxzIN88US=> MWKyOFg4QTd7Nh?=
Hs578T NES5cWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ZflEh|ryP Ml62OUBl MljESG1UVw>? NIXaTohKSzVyPEGg{txO NH3NWpIzPDh5OUe5Oi=>
LN18 NFPLWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHvT4gzOCEQvF2= NVfV[2NrPzJiaB?= NUjN[JA4TE2VTx?= M2L6PWlEPTB:NTFOwG0> NGPXe|AzPDd2MUC3OC=>
LN229 NIW0WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUiyNEDPxE1? NX\VVmd4PzJiaB?= MWXEUXNQ MVLJR|UxRDVizszN MkLmNlQ4PDFyN{S=
LNZ308 NHTobopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCyNEDPxE1? Mn\xO|IhcA>? NWDCcWsyTE2VTx?= MnzSTWM2ODx3IN88US=> M4XKWlI1PzRzMEe0
T98G NX\uWmFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGyNEDPxE1? NFH6UIk4OiCq MVTEUXNQ MVzJR|UxRDVizszN NXjxSXJkOjR5NEGwO|Q>
U87 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXzNlAh|ryP NIDFOJY4OiCq MWrEUXNQ MYTJR|UxRDVizszN NXjkW4xnOjR5NEGwO|Q>
LN18 NFK5WmZHfW6ldHnvckBCe3OjeR?= NVT5b3hyPSEQvF2= MlfkNlQhcA>? M3zYU2ROW09? MmPWTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? MmnlNlQ4PDFyN{S=
LNZ308 M3jTRWZ2dmO2aX;uJGF{e2G7 M33RR|Uh|ryP NXTOV4xROjRiaB?= MYrEUXNQ NXzLS3FjUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MXeyOFc1OTB5NB?=
Saos-2 MmizSpVv[3Srb36gRZN{[Xl? NYfxTYFmPTBizszN MlXZOFghcA>? M3XadmlvcGmkaYTzJINmdGxiaX72ZZNqd25? MYCyOFczPzZ4MB?=
MG-63 MXLGeY5kfGmxbjDBd5NigQ>? M4n4eFUxKM7:TR?= MmjiOFghcA>? NWm5dGVoUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MXeyOFczPzZ4MB?=
SJSA-1 NX;UeHBLTnWwY4Tpc44hSXO|YYm= M2q0b|UxKM7:TR?= MX60PEBp NVHmO4p5UW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M4DkWlI1PzJ5Nk[w
Saos-2 NEDsWJRHfW6ldHnvckBCe3OjeR?= MUG1NEDPxE1? NFLrSZk1QCCq NFfEZ4FKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NF;vOogzPDd{N{[2NC=>
MG-63 NX2xW2s{TnWwY4Tpc44hSXO|YYm= NIr6[pM2OCEQvF2= NIn1dpo1QCCq M2DjXGlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> MmnxNlQ4Ojd4NkC=
SJSA-1 MojrSpVv[3Srb36gRZN{[Xl? MnnHOVAh|ryP MV:0PEBp MoX2TY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> MViyOFczPzZ4MB?=
Saos-2 M{Lp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz1XHRUPTBizszN MX20PEBp MVnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NIi4bWQzPDd{N{[2NC=>
MG-63 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\jdHI2OCEQvF2= M2\KUVQ5KGh? MVrJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NHjXVFczPDd{N{[2NC=>
SJSA-1 M3PlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\LXWM2OCEQvF2= M1v6Z|Q5KGh? M4DTRmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NFWwOZkzPDd{N{[2NC=>
FaDu MVjGeY5kfGmxbjDBd5NigQ>? NHjFTm82KM7:TR?= NW\IO|FyOjRiaB?= NE\EeGdFVVOR MYfS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= MVeyOFY{OTF2Nx?=
EMT6 M1TYO2Z2dmO2aX;uJGF{e2G7 NVLFSlRpPSEQvF2= MWqyOEBp M{HtSGROW09? MkTIVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= M{ntclI1PjNzMUS3
HCT116 MX7GeY5kfGmxbjDBd5NigQ>? MYq1JO69VQ>? M{\S[VI1KGh? M2Lje2ROW09? NVTUUmJTWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NGPaTWUzPDZ|MUG0Oy=>
U87 MYHGeY5kfGmxbjDBd5NigQ>? NG\qfVk2KM7:TR?= MYOyOEBp M{PKXGROW09? MVzS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= NFrWUFMzPDZ|MUG0Oy=>
GBM M3XHTWFxd3C2b4Ppd{BCe3OjeR?= NYfsbmNqOs7:TR?= Mn\ROFhp M1P1UGROW09? M2DoVYlv\HWlZXSgbIlocGW{IHzleoVteyCxZjDhdI9xfG:|aYOsJIFv\CCmZXPy[YF{\WRiY3XscEB3cWGkaXzpeJk> NFzGOnozPDVyMES5Ni=>
BON MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexMVXPxE1? NYXDOlBoPzKq M{HyfIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> NIDESXMzPDR2M{WyNy=>
BON MUHBdI9xfG:|aYOgRZN{[Xl? MnfPNU02|ryP NX61elR{OjSq Mn7tbY5kemWjc3XzJIFxd3C2b4Ppdy=> M{mxcFI1PDR|NUKz
H1975 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmwMlMuQS54zszN MVy3Nog> NXexSGdqTE2VTx?= M3:5OGlEPTB;MT6zPFXPxE1? NWHSbXNwOjR|M{e4OFY>
H1975 MmPWRZBweHSxc3nzJGF{e2G7 NGrzWZEz|ryP M4H5VlI1cA>? M3jmR2ROW09? M33uOYlv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6 M{\sS|I1OzN5OES2
T-ALL NWfydI1pSXCxcITvd4l{KEG|c3H5 NWnCXYFD[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l NU\uNVN7OjRib4KgOFhp NEjuVJNFVVOR NH\IcZNi\m[nY4TzJJRp\SCSSUPLJJBifGi5YYmgbY4hXC2DTFygZ4VtdCCuaX7ldy=> NEHqcWszPDNzMEezOi=>
BCR-ABL NHrldlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLlO2wxNjJ3LUGw{txO NYTUZVJuPGR? NE\1b3R{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w M1nZb|I1OjR2NkGy
LC-1/SQSF M2TSXGZ2dmO2aX;uJGF{e2G7 MWOz{txO Mn;QNlRp NH;2NJZFVVOR NFjqUZhl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw> NH;yRmIzOzl6MEC5Ny=>
Primary CLL cells MlfYRZBweHSxc3nzJGF{e2G7 NInXOnYyNTFyzszN NHf5N2E1QGh? M1foSolv\HWlZYOgZZBweHSxc3nzJIlvKEOOTDDj[YxteyCrbnTldIVv\GWwdDDv[kBxem:pbn;zeIlkKG2jcnvldpM> MV[yN|g2ODhyNx?=
Primary CLL cells M4rSWmtqdmG|ZTDBd5NigQ>? MnHvNu69VQ>? MYSzNI1qdg>? MVTk[YNz\WG|ZXSgVGk{UyCjY4Tpeol1gQ>? NUTqTJNkOjN6NUC4NFc>
Primary CLL cells NYTWbGVXS3m2b4TvfIlkKEG|c3H5 MmjENu69VQ>? M1\vbFI1cA>? MnzxbY5lfWOnczDj[YxtKGO7dH;0c5hq[2m2eR?= NV7tR2VQOjN6NUC4NFc>
human NSCLC cell lines MUPBdI9xfG:|aYOgRZN{[Xl? M2[0V|AvOTJ3LUVOwG0> NYjFcYJHOjSq MoPDSG1UVw>? NHPBbm9KSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=> NIm4d5ozOzV4MkS3Ni=>
human HCC cell lines MoPDR4VtdCC4aXHibYxqfHliYYPzZZk> NYDsNlNZOC5yMEWtNe69VQ>? NHjX[3I1QGh? MmX6TWM2OD1zzszN NV\1N3ppOjN2OEm5PVk>
Huh7 M4exO2tqdmG|ZTDBd5NigQ>? NV\Nfo84Oc7:TR?= NETxd2w1QGh? NIHjeWV{cWewaf-shYNidnSueTDy[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDBb5Q> M4XvZ|I{PDh7OUm5
SK-HEP1 M{DWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxMVIx|ryP MkLMO|Jp M4G0Z2ROW09? MWHJR|Ux97zeMd88US=> MmX0NlM1PzlzM{[=
786-0 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjuT5YyNTJyzszN M4f6O|czcA>? Ml;ESG1UVw>? NIDFUJlKSzVy78{cNe69VQ>? MUGyN|Q4QTF|Nh?=
JVM2 M4G2dmN6fG:2b4jpZ4l1gSCjc4PhfS=> MnS4NE4zNTJyzszN NYLITmpGPzKq M2\s[WROW09? NY\qfmZOUUN3ME2wMlnPxE1? MWGyN|I{QDZ|OR?=
EHEB MljUR5l1d3SxeHnjbZR6KGG|c3H5 MWmwMlIuOjEQvF2= NHH3dJQ4Omh? MmDsSG1UVw>? MofUTWM2OD1yLkhOwG0> NE\FT5EzOzJ|OE[zPS=>
MEC2 NV:5R2g1S3m2b4TvfIlkcXS7IHHzd4F6 NU\PfmRlOC5{LUKw{txO Mof3O|Jp NWPW[5BFTE2VTx?= M3TUV2lEPTB;MD63{txO M3r5XVI{OjN6NkO5
primary B-CLL lymphocytes M1;HTWFxd3C2b4Ppd{BCe3OjeR?= M3K5VmlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? MmLqNlRp NEjkPHlFVVOR NYrJOWJHUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>? MX[yN|I{QDZ|OR?=
primary B-CLL lymphocytes MlLoT4lv[XOnIFHzd4F6 MmL5TWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? NVLndVBlOjSq NEHVe3pqdmirYnn0d{BxPzCVNlugKkA1TS2EUEGg[ZhxemW|c3nvci=> MVyyN|I{QDZ|OR?=
human NSCLC M1jhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT1XVUxNjVvMt88US=> MV63Nog> MX;JR|UxRTIQvF2= NU\RV3EyOjJ5OEGzPVM>
human NSCLC NITEe|dMcW6jc3WgRZN{[Xl? MnXSNe69VQ>? Mnz2NlRp M4HRbYlvcGmkaYTzJJRp\SCDa4SvcXRQWiC|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS= NVHPfVJMOjJ5OEGzPVM>
Y1 cell line M4jv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW4O2gxNjIQvF2vNe69VQ>? MYGyOIg> NHvIU2hFVVOR MojIbY5pcWKrdIOgOlDwxIViY3XscEB3cWGkaXzpeJkhcW5iTYnjMXNkfHJvdILhcpNn\WO2ZXSgZ4VtdHN? M4XOcFIzPjl{OUC0
PIK3CA-mutant MCF7 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HDSmdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P M1rETVczcA>? M{\1emdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P NXvtS|R{OjJ4NUO5Olc>
PIK3CA-mutant MCF7 NW\3NJNkU2mwYYPlJGF{e2G7 MVPJR|UxRTFzNNMxN45O MX23Nog> MkDWTWM2OD1zMUVCtVNvVSCrbjDy[YR2[2mwZzDBb5QheGixc4Doc5J6dGG2aX;uJIxmfmWucx?= Ml;2NlI3PTN7Nke=
MCF7-myr-Akt M1WwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTpS2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? NYfON|J3PzKq M4XjSGdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P NXyxTYpUOjJ4NUO5Olc>
colon cancer cell lines NWfCWmloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\uNE0yOM7:TR?= MmmxO|Jp MkTpSG1UVw>? MmfQTWM2OD1zzszN MWCyNlU1Ozh3Nx?=
gastric cancer cell lines MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMVEx|ryP M1XsZVczcA>? NIO1cVVFVVOR MVvJR|UxRTJvNd88US=> NEOzU|kzOjV2M{i1Oy=>
HCT-116/HT-29/MKN-45 MUPBdI9xfG:|aYOgRZN{[Xl? MVGy{txO M2rmcVQ5cA>? NYDQfIo2e2irZoSgbY4hTzJicHjhd4U> MUiyNlU1Ozh3Nx?=
HT-29 and HCT-116 NIPFeGxE[XOyYYPlJIF{e2G7 MlvEOe69VQ>? Ml7MNlRp M3zPeolv\HWlZYOgZ4F{eGG|ZTDhZ5Rqfmm2eR?= NGHWWYUzOjV2M{i1Oy=>
MM cell lines MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrNXWIyOM7:TR?= NH31[XAzPGh? M{TwdWROW09? MnfZTWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm M4XSW|IzOjB5NEi1
ARP-1 NYS0OJJ5SXCxcITvd4l{KEG|c3H5 NYH0eodKOTEQvF2= MX:yOIg> M2rOTWROW09? M4DEOolv\HWlZYOgUW0h[2WubDDhdI9xfG:|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36= M2LvOlIzOjB5NEi1
SNU-601 M4HSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvYVlJpPzKq MUDEUXNQ NXXlTopSUUN3ME2wMlgyPsLzMD6wOlPPxE1? NWDreWtGOjJzNUm4NVQ>
SNU-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKzO|Jp MmLzSG1UVw>? MkPGTWM2OD1zLkC4NuKyOC5yMklOwG0> Mn;mNlIyPTl6MUS=
SNU-668 NIHENXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rpeFczcA>? NVjsXlFGTE2VTx?= MWDJR|UxRTFwNUe5xtExNjB5NN88US=> M2[3V|IzOTV7OEG0
AGS NEnEd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq2XJA4Omh? NXyzT|NlTE2VTx?= NUHJe5FSUUN3ME2xMlcyPMLzMD6xNVfPxE1? MmTkNlIyPTl6MUS=
SNU-216 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj0ZmE4Omh? NEDwcWhFVVOR MmnvTWM2OD1{Lk[5NuKyOC5yOENOwG0> MnjWNlIyPTl6MUS=
SNU-5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPaO|Jp NHTrWXhFVVOR M3zsWGlEPTB;MT6zOVHDuTBwMEmx{txO MUSyNlE2QThzNB?=
SNU-638 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDqSWsyPzKq M17PdGROW09? NWjOV2N[UUN3ME2yMlI5OsLzMD6wOVPPxE1? NY\NcXFrOjJzNUm4NVQ>
SNU-16 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnsfWE4Omh? M4nIOWROW09? NHLJUYVKSzVyPUGuOVc{yrFyLkCwNe69VQ>? NUGweYs1OjJzNUm4NVQ>
SNU-484 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSwN|NbPzKq NGLZTHVFVVOR NYPCXolEUUN3ME2xMlczQMLzMD6wOFXPxE1? NUXIcHI1OjJzNUm4NVQ>
SNU-620 NGPQN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG3O|Jp Mmn4SG1UVw>? NIHzbHNKSzVyPUKuPVM6yrFyLkCwNe69VQ>? MXSyNlE2QThzNB?=
SNU-719 NIrR[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37zZ|czcA>? MWjEUXNQ MV3JR|UxRTNwMEO3xtExNjB|Mt88US=> MlXYNlIyPTl6MUS=
glioma cell lines MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK3Nog> MUjJR|UxRTFvMt88US=> NF;GUnYzOjB4NUC4NC=>
U87 MY\BdI9xfG:|aYOgRZN{[Xl? NFX6VIcz|ryP MkHlO|Jp M1LXR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiYX7kJINt\WG4ZXSgVGFTWCCjbnSgZ4F{eGG|ZT2z MX:yNlA3PTB6MB?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
細胞試験: [1]
+ 展開
  • 細胞株: A2780 cells.
  • 濃度: 0-6.6 μM
  • 反応時間: 3 days.
  • 実験の流れ: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: U87MG and A2780 xenografts are established in female nu/nu mice.
  • 製剤: In 15% Captisol.
  • 投薬量: ~60 mg/kg.
  • 投与方法: Dosed orally daily (q.d.).
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 順序で溶剤を入れること:
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 410.39
化学式

C18H21F3N6O2

CAS No. 944396-07-0
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Completed c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9, 2014 Phase 1|Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT02756247 Recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active, not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: Buparlisib (BKM120, NVP-BKM120)を買う | Buparlisib (BKM120, NVP-BKM120) ic50 | Buparlisib (BKM120, NVP-BKM120)供給者 | Buparlisib (BKM120, NVP-BKM120)を購入する | Buparlisib (BKM120, NVP-BKM120)費用 | Buparlisib (BKM120, NVP-BKM120)生産者 | オーダーBuparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)化学構造 | Buparlisib (BKM120, NVP-BKM120)分子量 | Buparlisib (BKM120, NVP-BKM120)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID